Kornimate/medical-research-clean huggingface dataset:
evaluating the effects of selective treatment utilizing flex-dosing for unresectable hcc with y90 sir-spheres

Conditions: Hepatocellular Carcinoma

Summary: the overall objective of this research study is to evaluate outcomes associated with flex-dosing in y90 sir-sphere administration in a prospective cohort of unresectable hcc patients eligible for segmental/super selective treatment at methodist dallas medical center (mdmc).

the overall objective of this research study is to evaluate outcomes associated with flex-dosing in y90 sir-sphere administration in a prospective cohort of unresectable hcc patients eligible for segmental/super selective treatment at methodist dallas medical center (mdmc). this study will enable physicians to be more precise in administering the correct radio-embolic dose, which will improve safety and efficacy of treatment while maintaining optimal dosing for tumor side effects. this study could potentially identify tumors earlier in the course of disease progression, which may result in more efficacious treatment and quality of life for patients. earlier diagnosis and treatment may result in decreased costs. this is a prospective cohort registry study. the prospective study cases will include all eligible y90 patients, who meet the inclusion criteria who are treated beginning in may 2020 to may 2022. follow-up of patients included in study will continue as needed in order to evaluate survival outcomes.

Eligibility criteria:
inclusion criteria: * age 18 years or older * all patients diagnosed with unresectable hcc in two of fewer hepatic segments at mdmc who undergo at least one sirt procedure with y-90 resin microspheres (sir-spheres®, sirtex medical limited, sydney, australia) will be included in data capture. hcc is considered unresectable if it is multifocal or bilobar, or if the patient has malignant portal vein thrombosis, portal hypertension, or decompensated liver disease (child-pugh b or c). * eligible cases for inclusion are those that would have undergone y-90 resin sirt and had an eastern cooperative oncology group (ecog) performance status score of 0 to 2; platelets \>60,000; creatinine \<2 mg/dl; bilirubin \<2 mg/dl; and international normalized ratio (inr) \<1.2. exclusion criteria: * subjects that do not meet the inclusion criteria * patients are not eligible for sirt if they had any extrahepatic disease; contraindication to hepatic artery catheterization such as vascular abnormalities, bleeding diathesis, allergy to contrast dye, concurrent malignancy, refractory ascites, previous external beam radiation, or evidence of any uncorrectable flow to the gastrointestinal tract; or greater than 30 gy of radiation estimated to be delivered to the lung based on angiography or tc-99 microaggregated albumin scan (shunt fraction of 20% or greater).
endovascular treatment for extra-large ischemic stroke

Conditions: Stroke, Acute Ischemic

Summary: the role of endovascular thrombectomy in patients with extra-large ischemic burden is still unclear. the xl stroke-2 randomized trial is aiming to investigate the efficacy and safety of mechanical thrombectomy in acute extra-large ischemic stroke patients with large vessel occlusion.

several randomized trials have shown that endovascular thrombectomy improve functional outcomes in acute ischemic stroke patients with large vessel occlusion. recently, six randomized controlled trials demonstrated the efficacy and safety of endovascular thrombectomy for large infarct patients (defined as alberta stroke program early computed tomography score \[aspects\] ≥3 or infarct core \<100ml). patients with extra-large infarct core (volume greater than 100 ml, aspects score of 0 to 2) accounted for a small proportion of these trials. therefore, the role of endovascular thrombectomy in patients with extra-large ischemic burden is still unclear. that is to say, exactly where the lower limit of endovascular thrombectomy is unknown. the xl stroke-2 randomized trial is aiming to investigate the efficacy and safety of mechanical thrombectomy in acute extra-large ischemic stroke patients with large vessel occlusion.

Eligibility criteria:
inclusion criteria: 1. age 18 years or older, and modified rankin scale score = 0 or 1 in patients 80 years or older; 2. acute ischemic stroke within 6 hours from last known well to randomization, or with negative mri-flair (no change on flair sequence and presence of infarct on mri-dwi) if \> 6 hours or unknown last known well time; 3. occlusion of the internal carotid artery, m1 or m2 segment of the middle cerebral artery confirmed by cta/mra/dsa; 4. baseline aspects score of 0-2 or infarct core volume ≥100ml; 5. the patient or patient's representative signs a written informed consent form. exclusion criteria: 1. ct or mr evidence of hemorrhage; 2. evidence of mass effect with ventricular effacement, midline shift or herniation on baseline imaging; 3. vessel tortuosity where it is expected that the thrombectomy device will not be able to reach the occlusion site or result in unstable access; 4. history of bleeding disorders, severe heart, liver or kidney disease, or sepsis; 5. currently participating in another investigational drug study; 6. any terminal illness with life expectancy less than 6 months.
the effect and prognosis of different operations on varicocele - a single-center clinical study

Conditions: Varicocele; Male Infertile;Varicocelectomy

Summary: the purpose of this study is to determine whether high ligation of spermatic vein by open operation and microsurgery for patients with are effective in the treatment of varicocele and to determine which surgical option is better.


Eligibility criteria:
inclusion criteria: * 1.infertile patient suffering from varicocele 2.severe varicocele patient with obvious symptoms 3.adolescents suffering from severe varicocele with or without orchiatrophy exclusion criteria: * 1.varicocele patient with abdominal infection 2.varicocele patient who has massive adhesion of pelvic tissue due to pelvic surgery history 3.mild varicocele 4.varicocele patient has no obvious symptoms if has have born children, suffer from idiopathic azoospermia，or their partner can't bear children

Keywords: varicocele; male infertile;varicocelectomy
japanese primary prevention of atherosclerosis with aspirin for diabetes (jpad) trial

Conditions: Coronary Disease; Arteriosclerosis; Diabetes Mellitus, Type 2

Summary: the purpose of this study is to determine the effects of low-dose aspirin for the primary prevention of vascular events in patients with type 2 diabetes in japan.

there is a worldwide epidemic of diabetes and the number of individuals with diabetes is set to increase further. as individuals with diabetes are at high risk of accelerated atherosclerosis and thrombotic vascular events, the significant proportion of the cardiovascular disease burden is projected to be among this population. jpad is a multicenter study with a prospective randomized open, blinded end-point (probe) design. the doses administered are aspirin 81 mg/day or 100 mg/day, the latter being enteric-coated aspirin. the primary objective was to compare the effect of aspirin on atherosclerotic events including cardiovascular events, cerebral vascular event, and other vascular events. we also analyze hemorrhagic events in this rct.

Eligibility criteria:
inclusion criteria: * patients have type 2 diabetes mellitus (30 or more years old and 85 years old or less). * patients give their informed consent to participate. exclusion criteria: * patient has electrocardiographic changes, including ischemic st-segment depression, st-segment elevation, or pathologic q waves. * patient has fixed ischemic heart disease, utilizing coronary angiography. * patient has cerebral vascular disease, including cerebral infarction, past hemorrhage, and experience of transient ischemic attack. * patient has arteriosclerotic disease, which needs internal medicine and/or surgical medical treatment. * patient has already taken the following anti-platelet or anti-thrombotic medicine: aspirin, ticlopidine, cilostazol, dipyridamole, trapidil, warfarin, and argatroban. * patient has severe gastric and/or duodenal ulcer. * patient has severe liver dysfunction. * patient has severe renal dysfunction. * patient has allergy for aspirin. * patient has atrial fibrillation. * pregnancy or the possible case of pregnancy.

Keywords: type 2 diabetes coronary heart diseases primary prevention atherosclerosis aspirin
treatment of unstable trochanteric fractures with the proximal femoral nail - antirotation (pfna)-asia

Conditions: Trochanteric Fractures

Summary: the primary objective of this prospective multicenter study is to assess any fracture fixation complication and revision rates during the clinical use of the proximal femoral nail antirotation asia (pfna asia) for the treatment of unstable trochanteric fractures.

from several studies, e.g. on hip prostheses, it is known that the asian population has other geometric proportions than caucasians, e.g. japanese woman have shorter femoral necks, smaller femoral neck angles and a more anterior bowing of the shaft than white americans. this was one of the reasons for the development of a new pfna asia with adapted sizes and geometry. no controlled clinical data are available whether the rate of mismatch and mismatch-related complications could be reduced.

Eligibility criteria:
inclusion criteria: * age 65 years and older * patients with isolated, unstable, closed trochanteric fractures, classified as ao 31-a2 or ao 31-a3 * definitive primary fracture treatment with pfna asia within 7 days sustaining the fracture (conversion from an external fixator to the pfna asia as an emergency procedure within the first week after the accident is allowed) * signed written informed consent (by the subjects or legal guardian) and agreement to attend the planned follow-ups * willing and able to comply with the post-operative management program * able to understand and read country national language at an elementary level exclusion criteria: * pathologic fracture * patients or legal guardian refusing to sign the informed consent form * patients with previous implants on the fractured hip and femur * drug or alcohol abuse * active malignancy * asa class v and vi * patients who are bed-ridden or wheel-chair ridden prior to injury event * neurological disorders and psychiatric disorders that would preclude reliable assessment (e.g., parkinson disease, multiple sclerosis, severe depression) * patients who have participated in any other device or drug related clinical trial within the previous month
comparison of two interdental devices for peri-implant plaque control

Conditions: Peri-implant Mucositis; Peri-Implantitis

Summary: this randomized clinical trial aims to compare the efficacy of two interproximal cleaning devices-superfloss and interdental brushes- in patients diagnosed with peri-implant diseases. the study evaluates plaque control and bleeding scores. patients will be randomly assigned to one of two oral hygiene protocols and will be monitored through clinical examinations and validated questionnaires assessing both clinical and radiographic parameters and patient-reported outcomes.

this single-center, randomized, parallel-arm clinical trial aims to compare the efficacy of superfloss and interdental brushes, used in combination with an electronic toothbrush, in patients with peri-implant diseases. participants will be randomly assigned to one of two oral hygiene protocols. clinical assessments will be performed at baseline, 6 weeks, and 3 months, including plaque index, bleeding scores, and probing depth. radiographic measurements and standardized patient-reported questionnaires (food impaction and oral hygiene self-efficacy) will also be used. the primary outcome is the reduction of plaque and gingival inflammatory scores at implant sites.

Eligibility criteria:
inclusion criteria: * age between 18 and 70 years * presence of at least one implant loaded for ≥1 year * presence of bleeding (≥1 site or line/profuse bleeding) and/or suppuration on gentle probing around the implant * systemically healthy adults * able to provide written informed consent exclusion criteria: * use of anticoagulants, anti-aggregants, antibiotics, or corticosteroids in the past 3 months * pregnant or lactating women * inability to perform adequate oral hygiene

Keywords: peri-implant mucositis peri-implantitis interproximal devices prevention
improving compliance with medical testing guidelines

Conditions: Breast Cancer; Cervical Cancer; Prostate Cancer; Colon Cancer; Lung Cancer

Summary: the study hypothesis is that clearer visual presentation of guideline recommendations and educational outreach, or academic detailing, can improve guideline compliance. however, it will investigate other aspects of screening-related decision-making, such as provider and patient beliefs about screening, provider-patient communication and patient's willingness to forgo expected testing. the research question is whether educational interventions can decrease non-compliance with screening guidelines for 5 common cancers.

this study is a cluster randomized trial that compares the immediate post-encounter impressions of 12 physicians and 18 of their patients about the discussion of screening for breast, cervical, colorectal, lung and prostate cancer as well as their beliefs about screening efficacy and patient reports of the screening experience. the interventions are educational materials and academic detailing (educational outreach) for providers. the investigators are particularly interested in contrasting the patient and provider recollections, the differential impact on underuse and overuse compliance and whether patient behaviors are consistent with their stated screening plans.

Eligibility criteria:
inclusion criteria: * patients: healthy men and women ages 30-89 seeing their primary care provider for routine visit * providers: non-pediatric primary care physicians from mount sinai beth israel or st. luke's-roosevelt associated practices exclusion criteria: * patient life expectancy of less than 1 year in primary care provider's judgment * inability to read and understand english * transgender status

Keywords: screening shared decision making
improvement of implant survival in total joint arthroplasty of the trapeziometacarpal joint

Conditions: Osteoarthritis

Summary: the study evaluates implant survival in total joint arthroplasty of the trapeziometacarpal (tmc) joint by monitoring the survival of different implant types using radiostereometry (rsa) evaluation of the implants.

the study evaluates implant survival and clinical outcome in total joint arthroplasty of the tmc joint. different implant designs are included in the study both cemented and uncemented implants. also the influence of patient factors and surgical technique on implant survival is investigated. the primary outcome is implant migration and loosening. evaluation is done by monitoring migration and loosening of different implant types using rsa evaluation of the implants. secondary outcomes are patient reported function evaluated with the disability of the arm, shoulder and hand score (dash) and visual analog pain score (vas). tertiary outcome is range of movement (rom) plus grip strength.

Eligibility criteria:
inclusion criteria: * patients with eaton type 2+3 tmc osteoarthritis exclusion criteria: * patients with eaton type 4 tmc osteoarthritis

Keywords: total joint arthroplasty thumb trapeziometacarpal joint osteoarthritis
treatment of splenic trauma: a retrospective cohort study

Conditions: Splenic Injury

Summary: in blunt trauma, the spleen is most frequent injured organ in the abdomen and the most frequent source of bleeding in the abdomen. historically, splenectomy was the treatment of choice for splenic bleeding. for exsanguinating patients, open splenectomy is still the proper choice of treatment if the spleen is a significant source of bleeding. however, for hemodynamic stable patients with splenic injury, non-operative management (nom) is an alternative, assuming they have no other indication for surgery (peritonitis). non-operative management includes observation and/or splenic artery embolisation (sae), but the indications for observation and sae varies between trauma centers. the greatest advantage of nom is the preservation of splenic function. in the investigators hospital splenic artery embolisation was introduced in 2007. the investigators want to describe the treatment of splenic injuries in their hospital, to see if the number of splenectomies has been recduced after 2007, and to see if sae has also been used in transferred trauma patients.


Eligibility criteria:
inclusion criteria: * all patients admitted at unn tromsø in the period of 01.01.2000 - 31.12.2013 and with the discharge diagnosis s36.0 splenic injury (icd-10) exclusion criteria: * no injury/coding error * iatrogenic injury * transfer \>7 days after injury * \>10 days between injury and first hospital admission

Keywords: spleen injury patient transfer splenectomy embolization, theurapeutic
a clinical trial on sequential immunization of recombinant covid-19 vaccine (cho cell, nvsi-06-09) and inactivated covid-19 vaccine (vero cell)

Conditions: COVID-19

Summary: a total of 516 healthy subjects aged 18 years and above who have been vaccinated with 2 doses/3 doses of inactivated covid-19 vaccine, will be enrolled, and randomly assigned to experimental group and control group in a 1:1 ratio, with 258 subjects in each sequential group.


Eligibility criteria:
inclusion criteria: * age: population aged 18 years and above; * judged by the investigator that the health condition is well after inquiry and physical examination; * vaccinated with 2 or 3 doses of inactivated covid-19 vaccine (vero cell vaccine) 6 months prior to study screening and according to product insert; * female participants who are not pregnant or nursing or at the time of enrolment (confirmed via negative urine pregnancy test), and do not have plans to become pregnant within the first 6 months after enrollment. effective contraceptive measures have been taken within 2 weeks before study inclusion and initiation; * be able and willing to provide written informed consent to participate in the study and complete all study requirements according to the study protocol; exclusion criteria: * covid-19 infection positive patients (including suspected or asymptomatic cases); * have a history of sars and mers infection; * have been vaccinated by any covid-19 vaccines other than vero cell vaccine； * have an axillary temperature 37.3 (forehead temperature 37.8℃℃); * have had previous allergic reactions to vaccination (such as acute allergic reactions, urticaria, eczema, dyspnea, angioneurotic oedema or abdominal pain) or allergy to known components of covid-19 vaccine; * history of thrombocytopenia or other coagulation disorders; * patients with known immunological impairment or immunocompromised. * received whole blood, blood products, plasma and/or immunoglobulin therapy within 3 months before study enrollment * have known or suspected severe illness such as respiratory illness, acute infection or active attacks of chronic illness, liver and kidney disease, severe diabetes mellitus, malignant tumour, infectious or allergic skin disease, human immunodeficiency virus (hiv) infection (test report available); * diagnosed with serious cardiovascular diseases such as cardiopulmonary failure, drug-uncontrolled hypertension (systolic blood pressure 160 mmhg and/or diastolic blood pressure 95 mmhg). * received live attenuated vaccines within 1 month before study enrollment; * received inactivated vaccines within 14 days before study enrollment; * received other investigational drugs within 6 months before study enrollment; * other vaccination-related contraindications considered by investigators.

Keywords: covid-19
a single mindfulness meditation session in preoperative anxiety : effects on the autonomous nervous system

Conditions: Anxiety; Relaxation

Summary: anxiety is an emotional disorder. it's a painful concern caused by uncertainty. it is a complex phenomenon misunderstood in spite of medical progress. relaxation is a technical for reduce anxiety and is effective and safe. previous study demonstrated the impact of session relaxation on the autonomous nervous system by the heart rate variability. primary objective of this new study is to demonstrate a link between heart rate variability and reduced anxiety during relaxation session.

it is monocentric, prospective and interventional study. this study will be proposed at the patients who will have an orthopedic surgery in full hospitalization. these patients are anxious because of surgery too. the day before surgery anesthetist save heart rate variability and value of the partial pressure of carbon dioxide during relaxation session.

Eligibility criteria:
inclusion criteria: * affiliated or entitled to a social security * have signed consent before their participation in the study * aged over 18 years * patients who will have an orthopedic surgery in full hospitalization * patients anxious on visual analogic scale of anxiety (\>5) exclusion criteria: * different disorder : disability to understand instructions, respiratory insufficiency, obesity, sleep apnea, wearing a pacemaker * medical history of schizophrenia or bipolar disorder

Keywords: preoperative anxiety relaxation autonomous nervous system surgery visual analogue scale (vas) state-trait anxiety inventory (stai-y)
assessment of efficacy and safety of perifosine, bortezomib and dexamethasone in multiple myeloma patients

Conditions: Multiple Myeloma

Summary: this is a randomized phase iii study to evaluate the efficacy and safety of perifosine when added to the combination of bortezomib and dexamethasone in multiple myeloma patients who have relapsed on a prior bortezomib treatment regimen.

a pre-planned interim analysis is expected to take place in q1 of 2013.

Eligibility criteria:
inclusion criteria: * patient was previously diagnosed with multiple myeloma based on standard diagnostic criteria. * patients must have relapsed (progressed \> 60 days) after their last dose of bortezomib-based therapy. in addition, patients may be relapsed or refractory to other non-bortezomib-based therapies. * patient has received at least 1 but not more than 4 prior anti-myeloma regimens and has progressive disease after the most recent treatment regimen. * patients must have adequate organ and marrow function. exclusion criteria: * patients must not be refractory to any bortezomib-containing regimen. * history of allergic reactions or intolerance attributed to compounds of similar chemical or biologic composition to perifosine (miltefosine or edelfosine), bortezomib or dexamethasone or any of their components. * prior treatment with perifosine or an investigational proteasome inhibitor. * chemotherapy or other therapy experimental or proven that is or may be active against myeloma within two weeks (14 days) prior to cycle 1 day 1.

Keywords: multiple myeloma relapsed multiple myeloma refractory multiple myeloma relapsed refractory multiple myeloma
oxytocin effects on cytokines and endocrine parameters after lps induced systemic inflammatory effects in healthy volunteers

Conditions: Sepsis

Summary: the aim of this study is to determine if oxytocin administration is able to blunt lps induced increase of cytokines (tnf-α) and if there is a change in the endocrine response after lipopolysaccharide administration in humans.


Eligibility criteria:
inclusion criteria: * men aged 18 years or older with no disease history * written informed consent exclusion criteria: * receiving any medication * probands who suffer from infectious disease

Keywords: oxytocin tnf sepsis lps